ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,570.77
-0.15%
Dow Jones
44,593.64
0.39%
Gold vs US Dollar
2,842.205
1.00%
Brent Oil
76.115
1.00%
Bitcoin
100,802.74
-0.62%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. XOMA Royalty Corporation (XOMAO) Share Price

XOMAO XOMA Royalty Corporation

25.26
-0.10 (-0.39%)
Last Updated: 18:47:44
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 XOMA Royalty Corporation NASDAQ:XOMAO NASDAQ Preference Share  Dep Shares Rep Series B 8.375% Cumulative PFD
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   -0.10 -0.39 25.26 25.26 25.40 25.37 25.26 25.3691 1,296 18:47:44   
 Sector  Turnover  Profit  EPS - Basic  PE ratio  Mkt Cap 
 Pharmaceutical Preparations 4.76M -40.83M -3.4653 -7.39 298.81M
 Type  Size  Price  Time  Units 
  189 25.26 18:47:44 USD
 
Pre-Market and After-Hours
Recent News
DateTimeSource
HeadlineMore XOMAO News
04/02/202512:30GLOBEXOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
19/12/202412:30GLOBEXOMA Royalty Declares Quarterly Preferred Stock Dividends
02/12/202412:30GLOBEXOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio
07/11/202412:30GLOBEXOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities
22/10/202412:00GLOBEXOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience
23/09/202410:30GLOBEZevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)
23/09/202409:30GLOBEXOMA Royalty Declares Quarterly Preferred Stock Dividends
Period
Draw mode
Data Downloads for XOMAO

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest XOMA Royalty Corporation Articles

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads